Drug Discovery & DDS– category –
-
Drug Discovery & DDS Weekly Report July 12, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report July 12, 2026 (PDF) — Download Weekly Report July 12, 2026 (PDF) — DownloadDownload 🎙 Podcast July 12, 2026 (... -
Drug Discovery & DDS Weekly Report July 5, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report July 05, 2026 (PDF) — Download Weekly Report July 05, 2026 (PDF) — DownloadDownload 🎙 Podcast July 05, 2026 (... -
2026 GLP-1 Agonist Pipeline Highlights Oral Orforglipron Approval and Retatrutide’s >28% Weight Reduction
Drug Discovery News USA Overview The 2026 GLP-1 agonist clinical pipeline is focusing on enhanced weight loss efficacy through novel mechanisms. Notably, Eli Lilly's oral small-molecule GLP-1 receptor agonist, orforglipron, received FDA ... -
AstraZeneca/Daiichi Sankyo’s Enhertu Receives EU Approval as First Tumor-Agnostic HER2-Directed ADC
AstraZeneca UK Overview AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), has received EU approval as the first tumor-agnostic HER2-directed therapy for patients with previously treated HER... -
Lonza Expands Commercial ADC Payload-Linker Manufacturing Capacity at Visp to Support Growing Oncology Pipeline
BioPharma APAC Switzerland Overview CDMO giant Lonza has announced significant expansion plans for its commercial antibody-drug conjugate (ADC) payload-linker manufacturing capacity at its Visp, Switzerland, site. This strategic investme... -
UBC-Led Global Review Reaffirms mRNA Vaccine Safety & Efficacy, Accelerating Applications in Cancer and Beyond
UBC News - The University of British Columbia Canada Overview An extensive global review led by researchers at the University of British Columbia has unequivocally reaffirmed the safety and efficacy of COVID-19 mRNA vaccines. Based on bi... -
Ohio State University Establishes “Buckeye BioLaunch,” an AI-Powered Center for Therapeutic Discovery, Development, and Commercialization
The Ohio State University USA Overview The Ohio State University announced the establishment of "Buckeye BioLaunch," a new center leveraging artificial intelligence (AI) to accelerate therapeutic discovery, development, and commercializa... -
First AI-Designed Drug Poised for FDA Approval by 2026-2027: Insilico Medicine’s IPF Candidate Leads
Oncodaily USA Overview The first AI-designed drug is increasingly likely to gain FDA approval between 2026 and 2027, with Insilico Medicine's rentosertib for idiopathic pulmonary fibrosis (IPF) identified as the leading candidate. Eli Li... -
FDA Approves Oral Carbapenem for cUTI and Combination Therapy for PTEN-Deficient Prostate Cancer in June 2026
Urology Times USA Overview In June 2026, the U.S. FDA announced multiple key approvals in urology, including the oral carbapenem antibiotic tebipenem pivoxil (Utebzi) for adult complex urinary tract infections (cUTI). Additionally, a com... -
FDA Grants Fast Track Designation to Multiple Oncology Drugs in May & June 2026, Including ADC for Metastatic Neuroendocrine Tumors
Oncology News Central USA Overview In May and June 2026, the U.S. FDA granted Fast Track designation to several novel oncology therapies, accelerating their development for serious conditions. Noteworthy designations include Zai Lab Limi...
